Amarin Corp Plc (AMRN)

[LONpharmacist]

h**p://w*w.fool.com/investing/general/2013/05/11/some-fish-oil-doesnt-help-some-patients-in-some-co.aspx

absolutely top quality article released by the fool (im sure some of you guys have read it) but it totally summed up my already known thoughts on that useless trial conducted in Italy

for one we over here in the UK use a book in pharmacy known as the BNF (also known as the british national formulary) it contains drug indications, side effects, dose regimens, safety information and interactions as well as recommendations from NICE (which determine first/second line treatments depending on what we call the cost:benefit ratio - aka is a drug worth the potential benefits)

anyway the main points that they derive from this study is firstly the awful way in which the patients were selected, infact some patients final outcome was so much higher then expected they had to change the endpoints midway in the trial
Also the trial was done in Italy whose dietary consumption, standard BMI and many other factors will hugely vary as opposed to Americans which is important because thats where Vascepa is targetting,
and finally the amount recommended in the BNF for Omacor (aka lovaza) is 4g daily, this study used "omega-3" fish oils at a dose of 1g daily - aka far below a therapeutic dose

therefore this study is useless